Xiao-Nan Hong
Overview
Explore the profile of Xiao-Nan Hong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
193
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xia Z, Lv F, Zhang Q, Liu Y, Zhang S, Liu C, et al.
Oncologist
. 2024 May;
29(9):819-e1223.
PMID: 38821519
Background: Pegylated liposomal doxorubicin (PLD) is a liposome-encapsulated form of doxorubicin with equivalent efficacy and less cardiotoxicity. This phase 2 study evaluated the efficacy and safety of the PLD-containing CHOP...
2.
Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer M, et al.
Hemasphere
. 2023 Jul;
7(7):e919.
PMID: 37404773
The phase III GALLIUM trial assessed the safety and efficacy of obinutuzumab-based versus rituximab-based immunochemotherapy in patients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL). At the...
3.
Jiang X, Yu F, Xue T, Xia Q, Bai Q, Yu B, et al.
Cancer Med
. 2023 Apr;
12(9):10684-10693.
PMID: 37081786
Purpose: Large B-cell lymphoma with IRF4 rearrangement (LBCL, IRF4+) has been recently recognized as a specific entity that is frequently associated with young age and favorable prognosis. However, whether the...
4.
Shi Y, Hong X, Yang J, Xu W, Huang H, Xiao X, et al.
Chin Med J (Engl)
. 2021 May;
134(11):1299-1309.
PMID: 33967195
Background: Bendamustine was approved in China on May 26th, 2019 by the National Medical Product Administration for the treatment of indolent B-cell non-Hodgkin lymphoma (NHL). The current study was the...
5.
Yan W, Jiang X, Wang W, Sun Y, Wo Y, Luo Z, et al.
Front Oncol
. 2020 Jun;
10:803.
PMID: 32582543
The well-established cell-of-origin (COO) algorithm categorizes diffuse large B-cell lymphoma (DLBCL) into activated B-cell-like (ABC) and germinal center B-cell-like (GCB) subgroups through gene expression profiling. We aimed to develop and...
6.
Liu Y, Luo P, Liu C, Xue K, Jin J, Xia Z, et al.
Onco Targets Ther
. 2019 Dec;
12:10469-10475.
PMID: 31819527
Objective: Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is relatively rare, and risk factors of this disease are still not well understood. This study aims to identify clinical features and...
7.
Liu Y, Xue K, Wang B, Li C, Lv F, Jin J, et al.
Leuk Lymphoma
. 2018 Oct;
60(4):934-939.
PMID: 30277105
Diffuse large B cell lymphoma is one of the predominant histological subtypes of primary gastric lymphomas. Factors that contribute to precise stratification and guide the treatment of this disease are...
8.
Luo Z, Wang Q, Peng W, Hu X, Hong X
Breast Care (Basel)
. 2014 Mar;
7(5):414-6.
PMID: 24647783
Background: For patients with anthracycline-resistant metastatic angiosarcoma, there is currently no available standard for second-line therapy, and a need exists for novel effective regimens to improve response rates. Case Report:...
9.
Kim S, Jung H, Chuang S, Hong H, Guo C, Cao J, et al.
J Hematol Oncol
. 2013 Nov;
6:86.
PMID: 24238138
Background: The gastrointestinal (GI) tract is one of the most common extranasal sites in extranodal NK/T-cell lymphoma (ENKTL). However, data regarding ENKTL involving the GI tract are relatively scarce. Thus,...
10.
Kim S, Hsu C, Song Y, Tay K, Hong X, Cao J, et al.
Eur J Cancer
. 2013 Aug;
49(16):3486-96.
PMID: 23910494
Background: Hepatitis B virus (HBV) reactivation is increasing, as rituximab has become widely used for B-cell lymphoma. Thus, prevention and management of HBV reactivation are important in HBV-endemic areas. Methods:...